Hunan Jingfeng Pharmaceutical Stock Forum

The recent 19% uptick might signal positive future trends. Yet, the company's disappointing five-year performance calls for improved fundamentals before enthusiasm. Investors should note the company's 2 warning signs.

The low P/S ratio may be due to declining revenue and projected industry growth. Current shareholders' acceptance of this ratio suggests no expected future revenue surprises. If recent revenue trends continue, significant share price movement seems unlikely.